HomeJudgments & SentencesSentencing StatementsHMA v MICHAEL FALCONER HMA v MICHAEL FALCONER At Edinburgh Sheriff Court Sheriff Crowe sentenced Michael Falconer to a 12 month Restriction of Liberty Order after he pled guilty to claiming Invalidity Benefit to which he was not entitled from 1 December 2003 to 19 March 2012 and obtaining a total of £32,272.50. On sentencing Sheriff Crowe made the following statement in court: “This was a gross breach of trust to claim invalidity benefit when working full time. I accept that some years ago you were injured in an industrial accident and were registered as a blind person. I understand however that this did not affect your ability to hold down a job as a foreman and read documents and correspondence. There are sentencing guidelines in place which were issued by the Appeal Court in 2010 which indicate that a fraud of this magnitude will normally be met with a prison sentence. I take into account your previous good record, the fact that you have been making repayments to the Department of Work and Pensions since the circumstances came to light and are able to make payment of a further £10,000 in the next few days.

I also note that the Crown has raised confiscation proceedings against you which are likely to secure the full sum assuming that your house is sold and funds are applied to the amount outstanding. Had the case proceeded to trial and no such payment been made a prison sentence of 2 years’ imprisonment would have been imposed. In the circumstances, including taking into account the early tendering of a plea of guilty and your vulnerability as a Registered Blind person in a prison setting I am prepared to impose a Restriction of Liberty order for 12 months with a curfew from 8 pm to 6 am each night. Your solicitor and the Crown have agreed to continue the confiscation proceedings until 12 March 2014 and I will review your Restriction of Liberty Order at that time to ensure that you are complying-bear in mind that it is a direct alternative to a prison sentence in view of the large amount of public money which was obtained by making false statements.” HMA v John Bowman Kennedy

Monday, 5 September, 2016 HMA v Justin Lee Lovell Friday, 2 September, 2016 HMA v Felix Tsotover Tuesday, 30 August, 2016 HMA v A & J Robertson Monday, 29 August, 2016 PF v Craig Lawson Friday, 26 August, 2016 Stay up-to-date with us Send to a friend This study is currently recruiting participants. (see Contacts and Locations) Allocation: RandomizedEndpoint Classification: Efficacy StudyIntervention Model: Parallel AssignmentMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)Primary Purpose: Treatment A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Genetics Home Reference related topics: core binding factor acute myeloid leukemia cytogenetically normal acute myeloid leukemia familial acute myeloid leukemia with mutated CEBPA

Drug Information available for: Genetic and Rare Diseases Information Center resources:Peekapoo Puppies For Adoption Acute Non Lymphoblastic LeukemiaCsueb Bookstore Hours Of Operation Overall survival [ Time Frame: Up to approximately 5 years ] [ Designated as safety issue: No ]Newborn Basset Hound Puppies For Sale Composite complete remission rate [ Time Frame: Through 1 month following last dose ] [ Designated as safety issue: No ] Event-free survival [ Time Frame: Up to approximately 5 years ] [ Designated as safety issue: No ] Leukemia-free survival [ Time Frame: Up to approximately 5 years ] [ Designated as safety issue: No ] Duration of remission [ Time Frame: Up to approximately 5 years ] [ Designated as safety issue: No ]

Type, incidence, severity, seriousness, and relatedness of adverse events [ Time Frame: Through 1 month following last dose ] [ Designated as safety issue: Yes ] Laboratory abnormalities [ Time Frame: Through 1 month following last dose ] [ Designated as safety issue: Yes ] Time to response [ Time Frame: Through 1 month following last dose ] [ Designated as safety issue: No ] Mortality rates at Day 30 and Day 60 post the first study treatment [ Time Frame: Day 30 and Day 60 following the first dose ] [ Designated as safety issue: No ] Minimal residual disease (MRD) status [ Time Frame: Up to approximately 5 years ] [ Designated as safety issue: No ] Estimated Study Completion Date: Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure) Experimental: 33A + HMA Active Comparator: placebo + HMA Hypomethylating agents (HMAs), such as decitabine or azacitidine, are considered a standard treatment for older patients with AML.

The primary goal of this study is to test whether patients treated with an HMA (either decitabine or azacitidine) in combination with 33A will survive longer than patients treated with an HMA in combination with placebo. Patients who meet eligibility criteria will be randomly assigned to one of two treatment groups: 1) 33A plus HMA (Experimental Arm); or 2) placebo plus HMA (Comparator Arm). In addition to evaluating survival, remission rates, duration of remission, event free- and leukemia-free survival, and safety and tolerability will be compared between arms. Ages Eligible for Study: 18 Years and older   (Adult, Senior) Genders Eligible for Study: Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL)) Intermediate or adverse cytogenetic risk Eligible for therapy with either decitabine or azacitidine

Acceptable hematologic and organ function AML associated with favorable risk karyotypes including inv(16), t(8;21), t(16;16), or t(15;17) Patients who are candidates for allogeneic stem cell transplant at the time of enrollment Patients with a history of one of the following myeloproliferative neoplasms: essential thrombocythemia, polycythemia vera, and primary myelofibrosis Received prior treatment with HMA or chemotherapy for antecedent myelodysplastic syndrome (MDS) Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies. Please refer to this study by its ClinicalTrials.gov identifier: NCT02785900 Contact: Seattle Genetics Trial Information Support Colorado Blood Cancer Institute

Denver, Colorado, United States, 80218 Principal Investigator: Michael Maris Shands Cancer Center / University of Florida Gainesville, Florida, United States, 32610 Contact: Marjorie McCall    352-273-6842    mmccall13@ufl.edu Principal Investigator: Maxim Norkin, MD Louisville, Kentucky, United States, 40202 Principal Investigator: Don Stevens, MD Boston, Massachusetts, United States, United States Principal Investigator: Kellie Sprague Washington University School of Medicine St. Louis, Missouri, United States, 63110 Contact: Megan Haney    314-454-8708    haneym@wustl.edu Principal Investigator: Camille Abboud, MD Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Principal Investigator: Jamie Koprivnikar Providence Portland Medical Center Portland, Oregon, United States, 97213 Principal Investigator: John Godwin, MD Saint Francis Hospital / Bon Secours